Class 2 Medicines Recall: Bristol Laboratories Ltd, Phenobarbital Bristol Labs 15mg Tablets, EL(24)A/50
Bristol Laboratories Ltd. are recalling one batch of Phenobarbital Bristol Labs 15mg Tablets as a precautionary measure due to the potential of contamination of small metallic particles within the tablets.
DMRC reference number
DMRC-32910584
Company name
Bristol Laboratories Ltd
Phenobarbital Bristol Labs 15mg Tablets, PL 17907/0175
SNOMED Code
21039211000001106
| Batch No | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| NU22001 | 10/2025 | 28’s | 21 Dec 2022 |
Active Pharmaceutical Ingredient: Phenobarbital
Brief description of the problem
Bristol Laboratories Ltd. are recalling one batch of Phenobarbital Bristol Labs 15mg Tablets as a precautionary measure due to the potential of contamination of small metallic particles within the tablets.
Bristol Laboratories have received one single market complaint relating to a tablet which had been cut in half by the patient prior to administration, revealing the small metallic particle within the tablet core. There have been no other similar reports related to this batch, since the batch was first distributed in December 2022. Whilst preliminary investigations indicate that this contamination is not widespread further investigations are necessary and ongoing. Bristol Laboratories consider it necessary however, to conduct a precautionary recall of the batch whilst such investigations are ongoing.
Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Advice for patients
No further action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.
Never stop taking medicines such as phenobarbital without medical advice, especially if they are being used for epilepsy. Suddenly stopping an epilepsy medicine may cause your seizures to start again or happen more often or last longer than before.
Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Further Information
For medical information enquiries please contact: [email protected]
For stock control enquiries please contact: [email protected]
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document